ICER finds Vertex's non-opioid pain drug 'slightly' cost-saving, with fewer addiction risks

The Institute for Clinical and Economic Review (ICER) on Monday unveiled a draft evidence report on Vertex Pharmaceuticals' suzetrigine (VX-548), finding the non-opioid pain drug "slightly cost-saving" compared to traditional pain medication, with savings largely due to averting cases of opioid-use disorder (OUD).